
|Articles|September 7, 2007
Glaucoma laser treatment ready to go to trial
Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.
Advertisement
Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.
The second-generation OT134 system is based on the company's smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already undergone successful testing on 23 patients in clinical trials. The OT134 upgrades have been designed to offer improved efficacy and ergonomics.
IOPtima plans to initiate a multinational, long-term, human clinical trial later this year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











